{"nctId":"NCT00864851","briefTitle":"Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease","startDateStruct":{"date":"2008-12-29","type":"ACTUAL"},"conditions":["Fabry Disease"],"count":44,"armGroups":[{"label":"Replagal 0.2 mg/kg, IV, every other week","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Replagal"]},{"label":"Replagal 0.2 mg/kg, IV, weekly","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Replagal"]},{"label":"Replagal 0.4 mg/kg, IV, weekly","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Replagal"]}],"interventions":[{"name":"Replagal","otherNames":["algasidase alfa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* \\>18 years-old;\n* Male:Fabry disease confirmed by deficiency of alfa galactosidase A activity OR Female:Fabry disease confirmed by a mutation of the alfa galactosidase A gene;\n* ERT-naÃ¯ve;\n* LVM/h \\> 50g/m2.7 for males and \\>47 g/m2.7 for females;\n* Negative pregnancy test at enrollment and contraception use required throughout study for female patients;\n* Signed informed consent;\n\nExclusion Criteria:\n\n* Class IV heart failure;\n* Clinically significant hypertension;\n* Hemodynamically significant valvular stenosis or regurgitation;\n* Morbid obesity;\n* Known autosomal dominant sarcoplasmic contractile protein gene mutation;\n* Treatment with any investigational drug or device within the 30 days;\n* Unable to comply with the protocol as determined by the Investigator;\n* Positive for hepatitis B, hepatitis C or HIV","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI)","description":"Left ventricular mass (LVM) was measured through echocardiography.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"12.5"},{"groupId":"OG001","value":"0.5","spread":"15.8"},{"groupId":"OG002","value":"-10.3","spread":"11.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 12 in Maximal Oxygen Consumption (VO2 Max) at Peak Exercise","description":"Exercise tolerance as measured by VO2 max at peak exercise using the standard exponential exercise protocol (STEEP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"3.24"},{"groupId":"OG001","value":"-0.3","spread":"4.76"},{"groupId":"OG002","value":"2.2","spread":"5.85"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 12 in Distance Walked in 6-Minute Walk Test (6MWT)","description":"Exercise tolerance using the 6MWT was measured as the total distance walked in 6 minutes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"87.7"},{"groupId":"OG001","value":"37.9","spread":"70.5"},{"groupId":"OG002","value":"24.7","spread":"45.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 12 in the Minnesota Living With Heart Failure Questionnaire (MLHF-Q) Summary Score","description":"Quality of life (QoL) was evaluated using the MLHF-Q, version 2. The questionnaire is designed to assess the degree to which heart failure symptoms affect a patient's daily life. The summary score ranges from 0 to 105, with a score of 105 representing the highest adverse impact on a patient's QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"16.7"},{"groupId":"OG001","value":"2.1","spread":"11.5"},{"groupId":"OG002","value":"-8.6","spread":"12.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 12 in New York Heart Association (NYHA) Functional Class","description":"The NYHA functional classification system relates symptoms to everyday activities and the patient's quality of life. NYHA Classification - The Stages of Heart Failure: Class I (Mild): No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). Class II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Class III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 12 in Plasma Globotriaosylceramide (GB3)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.046","spread":"2.256"},{"groupId":"OG001","value":"-2.132","spread":"4.363"},{"groupId":"OG002","value":"-2.076","spread":"1.248"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR)","description":"Renal function was assessed by an evaluation of change from baseline to Month 12 in eGFR as calculated using the Modification of Diet for Renal Disease (MDRD) equation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.2"},{"groupId":"OG001","value":"-3.3","spread":"12.7"},{"groupId":"OG002","value":"-1.7","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 12 in Urinary Albumin/Creatinine (A/Cr) Ratio","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":"624.82"},{"groupId":"OG001","value":"-54.1","spread":"322.51"},{"groupId":"OG002","value":"-54.2","spread":"294.86"}]}]}]},{"type":"SECONDARY","title":"Safety Evaluation","description":"Adverse events were collected throughout the study, from the time of informed consent to approximately 30 days post-final infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":20},"commonTop":["Fatigue","Nasopharyngitis","Cough","Pain in extremity","Headache"]}}}